镰状细胞病肺炎球菌疫苗接种半世纪:胜利还是免疫丧失?
本综述探讨镰状细胞病(SCD)患者中肺炎球菌疫苗的免疫学相互作用,重点关注疫苗诱导的低反应性、血清型替换及疾病流行病学演变。尽管肺炎球菌结合疫苗(PCV)显著减少疫苗型侵袭性肺炎球菌病(IPD),但非疫苗血清型持续致病及抗体持久性不足仍需更广覆盖和定制接种方案。高 valence 结合疫苗(如PCV20、PCV21)带来希望,但SCD人群的真实世界数据仍稀缺。
要点
- PCV通过T细胞依赖记忆应答改善免疫原性,显著减少SCD患者疫苗型IPD。
- PPSV23在SCD等免疫 compromised 人群中效果有限,重复或不当序贯接种可能诱导低反应性。
- 非疫苗血清型持续致病和抗体持久性不足,需更广血清型覆盖和定制免疫策略。
核心结论
- SCD患者仍面临不成比例的高肺炎球菌感染风险,需精准疫苗接种策略和纵向监测。
研究设计与样本
- 综述,检索范围未在摘要中明确报告。
主要发现
- PCV显著减少疫苗型IPD,但非疫苗血清型持续致病且抗体持久性欠佳。
- PPSV23在SCD等免疫 compromised 人群中效果有限,重复或不当序贯接种可能诱导低反应性。
- 高valence结合疫苗(如PCV20、PCV21)可扩大血清型覆盖并减少对PPSV23的依赖,但SCD真实世界数据稀缺。
临床怎么用
- SCD患者应优先采用PCV,并审慎评估PPSV23的使用时机与序贯方式以避免低反应性。
- 考虑使用高valence结合疫苗以扩大保护范围,同时加强抗体持久性和血清型替换的纵向监测。
局限性
- SCD人群中高valence结合疫苗的免疫原性、持久性和临床 efficacy 的真实世界数据仍稀缺。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite marked reductions in the rate of invasive pneumococcal disease (IPD) due to widespread use of penicillin prophylaxis and vaccination, individuals with sickle cell disease (SCD) remain at disproportionately high risk of pneumococcal infections. Pneumococcal conjugate vaccines (PCVs) have demonstrated improved immunogenicity over time by inducing T cell-dependent memory responses and have contributed significantly to reducing vaccine-type IPD in this population. However, persistent disease burden from non-vaccine serotypes and suboptimal antibody durability underscores the need for broader serotype coverage and a tailored immunization schedule. Until recently, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) was recommended for individuals with SCD to expand serotype protection. However, numerous studies indicate that PPSV23 has limited effectiveness in immunocompromised populations, including SCD, and may induce hyporesponsiveness when administered repeatedly or when inappropriately sequenced with PCVs. The approval of higher-valency conjugate vaccines (e.g., PCV20 and PCV21) offers promise for expanding serotype coverage while minimizing reliance on PPSV23. Nonetheless, real-world data on immunogenicity, durability, and clinical efficacy in SCD remain sparse. This review examines the intricate immunological interactions between PCVs and PPSV23 in the context of SCD, with a focus on vaccine-induced hyporesponsiveness, serotype replacement, and the evolving epidemiology of pneumococcal disease. It highlights the need for optimized evidence-based vaccination strategies and longitudinal monitoring among patients with SCD. A precision vaccination approach tailored to the unique immunological deficits of individuals with SCD will be essential to ensure sustained and comprehensive protection against pneumococcal disease.
引用
- Jamwal S, Omene B, Giri A, et al. Half a century of pneumococcal vaccination in sickle cell disease: Are we winning the battle or losing immunity? Vaccine. 2026. PMID: 42322679. doi:10.1016/j.vaccine.2026.128866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。